Yellox

RSS

bromfenac

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Yellox. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Yellox.

For practical information about using Yellox, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 15/09/2022

Authorisation details

Product details
Name
Yellox
Agency product number
EMEA/H/C/001198
Active substance
bromfenac sodium sesquihydrate
International non-proprietary name (INN) or common name
bromfenac
Therapeutic area (MeSH)
  • Pain, Postoperative
  • Ophthalmologic Surgical Procedures
Anatomical therapeutic chemical (ATC) code
S01BC11
Publication details
Marketing-authorisation holder
Bausch + Lomb Ireland Limited
Revision
11
Date of issue of marketing authorisation valid throughout the European Union
18/05/2011
Contact address

3013 Lake Drive
Citywest Business Campus Dublin 24,
D24PPT3
Ireland

Product information

04/02/2022 Yellox - EMEA/H/C/001198 - T/0031

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Treatment of postoperative ocular inflammation following cataract extraction in adults.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating